

available at www.sciencedirect.comjournal homepage: www.ejconline.com

Seven year update of an EORTC phase III trial of high-dose intensity M-VAC chemotherapy and G-CSF versus classic M-VAC in advanced urothelial tract tumours

C.N. Sternberg*, P. de Mulder, J.H. Schornagel, C. Theodore, S.D. Fossa, A.T. van Oosterom, J.A. Witjes, M. Spina, C.J. van Groeningen, B. Duclos, J.T. Roberts, C. de Balincourt, L. Collette, the EORTC Genito-Urinary Cancer Group

Department of Medical Oncology, San Camillo Forlanini Hospital, Nuovi Padiglioni, 4th floor, Circonvallazione Gianicolense 87, Rome 00152, Italy

ARTICLE INFO

Article history:

Received 21 July 2005

Accepted 12 August 2005

Available online 5 December 2005

Keywords:

Transitional cell carcinoma

Bladder cancer

M-VAC chemotherapy

Randomized trial

EORTC

ABSTRACT

EORTC protocol 30924 is an international randomized trial reporting a 7.3 year update of a 2 weekly regimen of high-dose intensity chemotherapy with M-VAC plus granulocyte colony stimulating factor (HD-M-VAC) compared to classic M-VAC in advanced transitional cell carcinoma (TCC). Two hundred and sixty three untreated patients with bidimensionally measurable TCC were included. In an intention to treat (ITT) analysis, there were 28 complete responses (CR) (21%) and 55 partial responses (PR) (41%), for an overall response rate (RR) of 64% on the HD-M-VAC arm. On M-VAC, there were 12 CR (9%) and 53 PR (41%), for an overall RR of 50%. The P-value for the difference in CR was 0.009; and for RR, was 0.06. After a median follow-up of 7.3 years, 24.6% are alive on the HD-M-VAC arm vs. 13.2% on the M-VAC arm. Median progression-free survival was better with HD-M-VAC (9.5 months) vs. M-VAC (8.1 months). The mortality hazard ratio (HR) was 0.76. The 2-year survival rate for HD-M-VAC was 36.7% vs. 26.2% for M-VAC. At 5 years, the survival rate was 21.8% in the HD-M-VAC vs. 13.5%. Median survival was 15.1 months on HD-M-VAC and 14.9 months on M-VAC. There was one death from toxicity in each arm; and more patients died to malignant disease in the M-VAC arm (76%) than in the HD-M-VAC arm (64.9%). With longer follow-up initial results have been confirmed, and shows that HD-M-VAC produces a borderline statistically significant relative reduction in the risk of progression and death compared to M-VAC.

© 2005 Elsevier Ltd. All rights reserved.

1. Introduction

In Europe, cancer of the bladder is the fourth most frequent cancer among men [1]. Systemic chemotherapy is the only modality that has been shown in phase III trials to improve survival in responding patients with advanced bladder cancer [2,3]. The M-VAC (methotrexate, vinblastine, adriamycin and

cisplatin) regimen, first reported in 1985 at Memorial Sloan Kettering Cancer Center (MSKCC), revealed that urothelial carcinoma was sensitive to chemotherapy [4]. Patients with measurable lesions were found to have a 72% response rate (RR) and 36% attained a complete response (CR) [5]. Long-term survival was achieved in patients who attained CR. Overall survival for the entire population was 13.1 months.

* Corresponding author. Tel.: +39 06 5870 4262; fax: +39 06 663 0771.

E-mail address: cstern@mclink.it (C.N. Sternberg).

0959-8049/\$ - see front matter © 2005 Elsevier Ltd. All rights reserved.

doi:10.1016/j.ejca.2005.08.032

Chemotherapy was more effective in patients with nodal disease than in those with visceral metastases [3,5].

In an update of 5 different M-VAC regimens from MSKCC 194/203 patients were evaluable; 46 patients achieved CR (24%) and 84 patients PR (43%), with overall RR of 67%. The median survival for all 203 patients was 14.8 months, with a 5-year survival rate of 17% [6]. The 5-year survival for 46 CR patients after chemotherapy alone was 40%. An additional 30 patients achieved CR after chemotherapy was followed by surgery with a 5-year survival rate of 33% [7].

Prognostic factors were predictive of response and survival in these patients. Three risk categories on the basis of Karnofsky performance status (KPS) and the presence or absence of visceral metastases. Two factors had independent prognostic value: KPS less than 80%; and visceral (lung, liver, or bone) metastasis. Median survival times for patients who had 0, 1, or 2 risk factors were 33, 13.4, and 9.3 months, respectively ($P = 0.0001$). The median survival time of patient cohorts could vary from 9 to 26 months simply by altering the proportion of patients from different risk categories [6].

In an attempt to improve upon the results obtained with M-VAC chemotherapy, the present trial was initiated as a randomized phase II trial in June 1993 evaluating toxicity and activity and became a randomized phase III trial from April 1996 until November 1998. European Organization for the Research and Treatment of Cancer (EORTC) Genitourinary Group members from institutions in 8 countries participated in this protocol. The 3.2 year median follow-up results were first reported at ASCO in 2000 and published in 2001 [8]. The primary objective was to demonstrate an improvement in survival with HD-M-VAC. The current report seeks to update our experience with a median follow-up in both groups of 7.3 years.

2. Patients and methods

Patients with bidimensionally measurable distant metastases or unresectable TCC of the urinary tract (bladder, ureter, or renal pelvis) with no prior systemic cytotoxic or biologic treatment, and a WHO performance status of 0 or 1 were eligible for this trial. Patients were randomized 1:1 between HD-M-VAC which consisted of Methotrexate (MTX) 30 mg/m² d 1, Vinblastine (VLB) 3 mg/m² d 2, Adriamycin (ADM) 30 mg/m² d 2 and Cisplatin (CDDP) 70 mg/m² d 2 with Granulocyte Colony Stimulating Factor (G-CSF) administered on days 3–7 every 15 days vs. M-VAC (MTX 30 mg/m² d 1; VLB: 3 mg/m² d

2; ADM: 30 mg/m² d 2; and CDDP 70 mg/m² d 2 with MTX and VLB on d 15 and 22) every 28 days (Fig. 1).

Stratification was according to the treating institution and WHO performance status. The main endpoint of the phase III trial was overall survival. Secondary endpoints included progression-free survival, time to progression, response rate and toxicity. The objective of the trial was to detect a relative difference of 50% in median overall survival between the two arms from 12 months to 18 months (hazard ratio = 0.67). This corresponds to an absolute difference of 13% at the time of the median. With a two-sided logrank test at the 5% significance level and 80% power this objective required 192 events (deaths).

All analyses were carried out according to the intent-to-treat principle and statistical significance was claimed at the two-sided 0.05 level. Time to event comparisons were performed using the logrank test. Estimation of survival curves was by the Kaplan–Meier technique. Comparison of distribution of binary and non-ordered categorical variables was performed using the χ^2 test and that of continuous variables using the Wilcoxon Rank Sum test. Comparison of ordered categorical variables was performed using a χ^2 test for linear trend.

The intended dose–intensity ratio can be found in Table 1. With HD-M-VAC the dose intensity of ADM and DDP is doubled, but only 70% of the MTX and VLB dose are given compared to M-VAC (Table 1).

3. Results

Patient characteristics were well balanced between the two groups and are described in Table 2. One hundred and thirty four patients were randomized to the HD-M-VAC arm and 129 patients to the M-VAC arm. The median WHO Performance Status was 1. 40% and 31% had visceral metastases; 60% and 69% did not have lung, liver or bone metastases; 20% and 15% had prior radiation therapy; and 73% and 75% had prior surgery, respectively, for HD-M-VAC and M-VAC arms.

Generally, the patients who participated in this trial were very ill, with widely distributed metastatic disease. Sites of disease were equally distributed between the two arms (Table 3). Only 1/3 of patients had only one measurable disease site; and approximately 2/3 had two or more disease sites. The majority of patients in both arms had abdominal masses (pelvic, extranodal, and retroperitoneal). There were more patients in the M-VAC arm with lung metastases (29% vs. 12%)




Fig. 1 – Trial design. Standard M-VAC is given every 28 days. High-dose M-VAC + G-CSF is given every 15 days.

Table 1 – Dose intensity

	M-VAC Q14 days mg/m ²	HD-M-VAC Q 14 days mg/m ²	Dose intensity
MTX	45	30	0.7×
VLB	4.5	3	0.7×
ADM	15	30	2.0×
CDDP	35	70	2.0×

MTX, Methotrexate; VLB, Vinblastine; ADM, Adriamycin; CDDP, Cisplatin.

Table 2 – Baseline characteristics

	M-VAC n = 129	HD-M-VAC n = 134	P-value
Age	62 (32–81)	61 (36–76)	0.231
Males:females	107:22	105:29	0.347
Median WHO PS	1 (0–2)	1 (0–2)	0.482
Visceral metastases	47 (36%)	37 (28%)	0.125
Prior RT	26 (20%)	20 (15%)	0.275
Prior surgery	94 (73%)	100 (75%)	0.828
Primary tumour site			
Bladder	106 (82%)	118 (88%)	0.411
Renal pelvis	15 (23%)	10 (8%)	
Ureter	6 (5%)	4 (3%)	
Urethra	2 (2%)	1 (1%)	
Prostatic ducts	0 (0%)	1 (1%)	
Bajorin Risk Group			
Low	77 (60%)	87 (65%)	0.667
Intermediate	45 (35%)	40 (30%)	
High	7 (5%)	7 (5%)	

Table 3 – Involved disease sites

	M-VAC n = 129 (%)	HD-M-VAC n = 134 (%)	P-value
Abdominal masses	71	66	0.223
Primary site	34	44	0.078
Lung	29	12	<0.001
Liver	10	10	0.921
Superficial LN	9	9	0.902
Med LN	5	5	0.723
Bone	5	10	0.114
Skin/s.c. mets	3	2	0.664
Number of involved sites			
1	36	37	0.089
2	28	38	
3	19	14	
4+	16	19	

and more in the HD-MVAC arm with bone metastases (10% vs. 5%). The risk distribution for the two groups was equally distributed according to the Bajorin risk criteria ($P = 0.667$) [6].

The duration of treatment was shorter with HD-M-VAC, 12 weeks vs. 21 weeks, and the median number of cycles was 6 vs. 4 with M-VAC. The average cycle duration time was 15 days (13–27 days) vs. 31 (27–47 days) for HD-M-VAC and M-VAC, respectively.

There was a trend towards more whole blood cell (WBC) toxicity in the M-VAC arm, as compared to the HD-MVAC arm, most probably due to the G-CSF. In the HD-M-VAC arm,

only 20% of the patients had G3-4 WBC toxicity. More than 70% in the M-VAC arm had no G 2-4 thrombocytopenia, at any time during their course, as was true for >60% of patients in the HD-M-VAC arm (Table 4). There was one toxic death in each arm. There were no significant differences in terms of mucositis or creatinine levels.

The response rates were significantly better in the HD-M-VAC arm. An objective CR or PR was obtained in 72% of patients on the HD-M-VAC arm as compared to 58% for M-VAC; comparison of CR + PR rate $P = 0.016$ (2-sided). Of particular interest, the CR rate was 25% with HD-M-VAC as compared to 11% with M-VAC. The P -value for the difference in the CR rate was 0.006 (2-sided) (Table 5).

At a median follow-up of 7.3 years, 213 of 263 (81%) of patients have died. 24.6% are alive on the HD-M-VAC arm vs. 13.2% on the M-VAC arm. Progression free survival is illustrated in Fig. 2. By intent-to-treat analysis, median progression-free survival was better with HD-M-VAC: 9.5 months (95% CI 7.6–12.2) vs. M-VAC 8.1 months (95% CI 7.0–9.9) months ($P = 0.017$; HR = 0.73; 95% CI 0.56–0.95).

Overall survival can be found in Fig. 3. The median survival was 15.1 months as compared to 14.9 months and the mortality HR was 0.76 (95% CI: 0.58–0.99). The 2-year survival rate for HD-M-VAC was 36.7% (28.3–45.0%) vs. 26.2% for M-VAC (95% CI, 18.4–34.0%). At 5 years, survival was 21.8% in the HD-M-VAC arm (95% CI :14.5–29.2%) vs. 13.5% (95% CI 7.4–19.6%; $P = 0.042$). More patients died from malignant disease in the M-VAC arm 76% vs. 64.9% in the HD-M-VAC arm.

Table 4 – Treatment toxicity

Hematologic toxicity	Grade	M-VAC n = 129	HD-M-VAC n = 134	P-value
WBC	2	28 (22%)	28 (21%)	<0.001
	3	59 (46%)	16 (12%)	
	4	21 (16%)	11 (8%)	
Platelets	2	15 (12%)	22 (16%)	0.033
	3	14 (11%)	14 (11%)	
	4	8 (6%)	14 (11%)	
Neutropenic fever		33 (26%)	13 (10%)	<0.001
Received G-CSF at least once		24 (19%)	126 (94%)	
Mucositis	2	26 (20%)	24 (18%)	0.034
	3	18 (14%)	12 (9%)	
	4	4 (3%)	1 (1%)	
Creatinine	2	3 (2%)	2 (2%)	0.815
	3	4 (3%)	5 (4%)	

Table 5 – Response rates

	M-VAC n = 129	HD-M-VAC n = 134	P-value
No. evaluable	113 (88%)	114 (85%)	
CR + PR	65 (58%)	83 (72%)	0.016 (2-sided)
CR	12 (11%)	28 (25%)	0.006 (2-sided)
PR	53 (47%)	55 (48%)	




Fig. 2 – Progression-free survival.




Fig. 3 – Overall survival.

4. Discussion

Table 6 describes the randomized trials in the literature which have sought to improve upon the results with M-VAC chemotherapy. The Gemcitabine-Cisplatin (GC) combination

has been shown to have similar results with a better toxicity profile and has become a widely accepted second standard chemotherapy regimen [9].

Triplet regimens have been evaluated primarily in phase II settings with promising results. The Spanish regimen of gemcitabine, cisplatin, and paclitaxel (GCP) led to a RR of 78% [10]. In the multi-center phase II study, median survival was 15.6 months [11]. Another combination of gemcitabine, paclitaxel, and carboplatin (rather than cisplatin) was evaluated in the USA and compared favorably with a 14.7 month median survival and 1-year survival of 59%. The RR was 68% (CR 32% and PR 36%) [12]. And yet a third phase II study from MSKCC, ifosfamide, paclitaxel (Taxol), and cisplatin (Platinum) (ITP) produced a 68% RR (CR 23% and PR 45%). Median survival was 20 months [13].

It is well known that phase II trial results are often better than those achieved in the phase III setting, primarily due to patient selection. However, they may point to an important indication of efficacy requiring verification in phase III trials. One such trial comparing GCP to GC will shortly be completed by the Genitourinary Group of the EORTC with collaboration from the Southwest Oncology Group (SWOG).

In conclusion, in this study up-date, HD-M-VAC given every 2 weeks with G-CSF was compared in a phase III randomized trial to M-VAC. It was possible to deliver twice the dose of cisplatin and doxorubicin with less toxicity, fewer dose delays, and in half the time if G-CSF was routinely added. One could conjecture that this regimen might be useful in the neoadjuvant or adjuvant setting, since the cycle length is much shorter and it is delivered in half the time of traditional M-VAC. This trial revealed less toxicity with high-dose M-VAC due to the addition of G-CSF. A significant difference in favour of HD-M-VAC was seen in overall RR and in the CR rates. The 5-year survival was 21.8% with HD-M-VAC compared to 13.5% with M-VAC. At a follow up of 7.3 years, the HD-M-VAC regimen revealed an excellent toxicity profile, an improvement in the CR rate and in progression-free survival.

Conflict of interest statement

None declared.

Table 6 – Phase III randomized trials in urothelial cancer

Author	Chemo	n	RR (%)	MDS	Comments
Loehrer [2]	M-VAC	126	39	12.5	M-VAC > DDP
	DDP	120	12	8.2	
Logothetis [3]	M-VAC	65	65	12.6	M-VAC > CISCA
	CISCA	55	46	10.0	
Von der Maase [9]	M-VAC	202	46	14.8	M-VAC ~ GC
	GC	203	49	13.8	
Bamias [14]	M-VAC	109	54	14.2	M-VAC
	DC	111	37	9.3	
Sternberg [this paper]	HD-M-VAC	134	72	15.1	HD-M-VAC > M-VAC
	M-VAC	129	58	14.9	
Bellmunt [not yet published]	GCP				Too early
	GC				

Acknowledgements

This publication was supported by Grants No. 5U10-CA11488-22 through 5U10-CA11488-35 from the National Cancer Institute (Bethesda, MD, USA). Its contents are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute. Contributing institutions: San Camillo and Forlanini Hospitals, Roma – UMC St. Radbound, Nijmegen – AVL, Amsterdam, Gustave Roussy, Villejuif – Radiumhospital, Oslo – Cent. Di Rif. Oncol, Aviano AZ VU, Amsterdam – Hosp Civil, Strasbourg – Freeman, Newcastle – OSP.MACCHI, VARESE, Erasmus, Rotterdam, UZ, Leuven – UZ, Antwerpen – AMC, Amsterdam – Klinikum Nuremberg-Bosch Medicentrum – Hosp. Nuestra, Las Palmas – University, Palermo – Leon Berard, Lyon-mediz Fakultat, Aachen.

REFERENCES

- Boyle P, Ferlay J. Cancer incidence and mortality in Europe, 2004. *Ann Oncol* 2005;16(3):481–8.
- Loehrer P, Einhorn LH, Elson PJ, et al. A randomized comparison of cisplatin alone or in combination with methotrexate, vinblastine, and doxorubicin in patients with metastatic urothelial carcinoma: a Cooperative Group Study. *J Clin Oncol* 1992;10:1066–73.
- Logothetis CJ, Dexeus F, Finn L, et al. A prospective randomized trial comparing CISCA to MVAC chemotherapy in advanced metastatic urothelial tumours. *J Clin Oncol* 1990;8:1050–5.
- Sternberg CN, Yagoda A, Scher HI, et al. Preliminary results of methotrexate, vinblastine, adriamycin and cisplatin (M-VAC) in advanced urothelial tumours. *J Urol* 1985;133:403–7.
- Sternberg CN, Yagoda A, Scher HI, et al. M-VAC for advanced transitional cell carcinoma of the urothelium: efficacy, and patterns of response and relapse. *Cancer* 1989;64:2448–58.
- Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. *J Clin Oncol* 1999;17(10):3173–81.
- Dodd PM, McCaffrey JA, Herr H, et al. Outcome of postchemotherapy surgery after treatment with methotrexate, vinblastine, doxorubicin, and cisplatin in patients with unresectable or metastatic transitional cell carcinoma. *Clin Oncol* 1999;17(8):2546.
- Sternberg CN, de Mulder PHM, Schornagel JH, et al. Randomized phase III trial of high-dose intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus classic MVAC in advanced urothelial tract tumours: European Organization for Research and Treatment of Cancer Protocol No. 30924. *J Clin Oncol* 2001;19(10):2638–46.
- von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. *J Clin Oncol* 2000;18(17):3068–77.
- Bellmunt J, Guillem V, Paz-Ares L, et al. Phase I-II study of paclitaxel, cisplatin, and gemcitabine in advanced transitional-cell carcinoma of the urothelium. *J Clin Oncol* 2000;18(18):3247–55.
- Bellmunt J, de Wit R, Albiol S, et al. New drugs and new approaches in metastatic bladder cancer. *Crit Rev Oncol Hematol* 2003;2:195–206.
- Hussain M, Vaishampayan U, Du W, et al. Combination paclitaxel, carboplatin, and gemcitabine is an active treatment for advanced urothelial cancer. *J Clin Oncol* 2001;19(9):2527–33.
- Bajorin DF, McCaffrey JA, Dodd PM, et al. Ifosfamide, paclitaxel, and cisplatin for patients with advanced transitional cell carcinoma of the urothelial tract: final report of a phase II trial evaluating two dosing schedules. *Cancer* 2000;88(7):1671–8.
- Bamias A, Aravantinos G, Deliveliotis C. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study from the Hellenic Cooperative Oncology Group. *J Clin Oncol* 2004;22:220–8.